Benchmark Holdings PLC (LON:BMK) said that the MRL (Maximum Residue Limit) for its novel sea lice treatment BMK08 has been ratified under European Law.
The MRL confirms the safety of Benchmark's sea lice solution for consumers and represents a significant milestone in the regulatory approval process towards the anticipated commercial launch of BMK08 and CleanTreat in Norway, said the statement.
The commercial launch remains subject to the grant of a Marketing Authorisation in Norway.
Sea lice are among the biggest biological challenge in salmon farming, said Benchmark, and the MRL EU ratification is the culmination of almost a decade of research and development.
Trond Williksen, chief executive, added: "The ratification of the MRL is a further stepping stone towards commercialisation following the announcement of our first customer agreements for CleanTreat in March.”
Benchmark's solution addresses the sea lice challenge in a sustainable way both in terms of animal welfare and environmental impact, he said.